In previous treat-to-target trials, adjustments to the dose of basal insulin have been made at least weekly, according to ...

Semaglutide at a dose of 2.4 mg has established weight-loss and cardiovascular benefits, and cagrilintide at a dose of 2.4 mg ...

Musunuru and colleagues 1 describe in the Journal an innovative approach in which gene editing is applied in the treatment of a very rare disease, the severe urea-cycle disorder carbamoyl ...

Corporatization” of health care, a process predicted decades ago, now refers to the general trend throughout the industry toward higher levels of integrated control by consolidated profit-seeking ...

A 63-year-old woman was evaluated for dyspnea and edema. Soft-tissue thickening was noted in the retroperitoneum and mediastinum and around the heart and vessels. A diagnosis was made.

One of the more difficult decisions for patients with poorly controlled type 2 diabetes, as well as for their clinicians, is ...

We conducted a phase 2, double-blind, randomized, placebo-controlled, dose-ranging trial that included 11 groups as two cohorts. Participants with obesity (obesity cohort) were randomly assigned ...

NEJM uses highly rigorous editorial, peer, and statistical review processes to evaluate manuscripts for scientific accuracy, novelty, and importance.

A.J. Cruz-Jentoft and D. VolkertN Engl J Med 2025;392:2244-2255 ...

Type 1 diabetes mellitus is a chronic metabolic disease resulting from autoimmune destruction of pancreatic beta cells. More than half the cases of type 1 diabetes are diagnosed in adulthood; 62% ...